Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Exuma Reports Positive Early Results from China Trial of Conditionally Active Biologics

publication date: May 21, 2019

Exuma Biopharma, a German-China company, announced early positive results from a China Phase I trial of two CAR-T candidates in patients with solid tumor cancers. The trial, which enrolled subjects with advanced renal cell carcinomas, tested two conditionally active CAR-T products, CCT301-38 (AXL) and CCT301-59 (ROR2). Exuma said the products are the first CABs to be tested in humans. Both CABs turn the growth inhibitory acidic tumor microenvironment into one activating signal, followed by the activation of the target antigen (AXL or ROR2). More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here